Capmatinib
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 298 publications
Capmatinib for High-Level MET-Amplified Metastatic Gastric Cancer Identified by Comprehensive Genomic Profiling: A Case Report and Literature Review.
Journal: Journal of gastrointestinal cancer
Published: June 28, 2026
Targeting MET in 2025: From Exon 14 Skipping to MET-Amplified Acquired Resistance in Non-Small Cell Lung Cancer.
Journal: International journal of molecular sciences
Published: May 01, 2026
Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.
Journal: Lung cancer management
Published: April 04, 2026
A novel NIR fluorescent probe based on p-mercaptophenylboronic acid-functionalized copper nanoclusters for capmatinib quantification.
Journal: Analytical methods : advancing methods and applications
Published: March 30, 2026
A pretreatment 15-gene signature predicts non-pCR in response to neoadjuvant chemotherapy in breast cancer and reveals a pyruvate-CCND1-MET therapeutic vulnerability.
Journal: Frontiers in oncology
Published: March 17, 2026
Simultaneous Determination of Capmatinib and Resveratrol via Micellar-Enhanced Synchronized Fluorescence Spectroscopy: Application to Human Plasma and Environmental Water Samples.
Journal: Luminescence : the journal of biological and chemical luminescence
Published: January 29, 2026
A tri-scale in silico framework integrating pharmacovigilance and mechanistic modeling suggests tepotinib-associated acute kidney injury risk.
Journal: Renal failure
Published: January 25, 2026
Targeting MET in non-small cell lung cancer brain metastases: from molecular mechanism to precision therapy.
Journal: Journal of translational medicine
Published: January 19, 2026
Association of MUC3A P258S mutation with advanced phase CML structural and in silico insights.
Journal: Functional & integrative genomics
Published: January 09, 2026
Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer by concurrent integrin and MET signaling.
Journal: Science signaling
Published: December 23, 2025
Safety and Synergy of Capmatinib Plus Stereotactic Radiotherapy in MET Exon 14-Mutated Non-Small Cell Lung Cancer: A Case Report.
Journal: Cureus
Published: December 20, 2025
Last Updated: 09/26/2026